Joseph Michael Fitzgerald - 13 Feb 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
13 Feb 2026
Net transactions value
-$2,757,537
Form type
4
Filing time
18 Feb 2026, 17:58:50 UTC
Previous filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fitzgerald Joseph Michael EVP & Group Pres, Cardiology 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH /s/ Susan Thompson, Attorney-in-Fact 18 Feb 2026 0001484186

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Award $0 +34,898 +21% $0.000000 204,790 13 Feb 2026 Direct F1
transaction BSX Common Stock Award $0 +34,898 +17% $0.000000 239,688 13 Feb 2026 Direct F2
transaction BSX Common Stock Options Exercise $0 +2,797 +1.2% $0.000000 242,485 13 Feb 2026 Direct F3
transaction BSX Common Stock Tax liability $2,473,862 -33,104 -14% $74.73 209,381 13 Feb 2026 Direct
transaction BSX Common Stock Options Exercise $0 +4,362 +2.1% $0.000000 213,743 14 Feb 2026 Direct F3
transaction BSX Common Stock Tax liability $148,713 -1,990 -0.93% $74.73 211,753 14 Feb 2026 Direct
transaction BSX Common Stock Options Exercise $0 +3,960 +1.9% $0.000000 215,713 16 Feb 2026 Direct F3
transaction BSX Common Stock Tax liability $134,962 -1,806 -0.84% $74.73 213,907 16 Feb 2026 Direct
holding BSX Common Stock 5,234 13 Feb 2026 By Child F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Restricted Stock Units Options Exercise $0 -2,797 -25% $0.000000 8,391 13 Feb 2026 Common Stock 2,797 Direct F3, F5
transaction BSX Restricted Stock Units Options Exercise $0 -4,362 -50% $0.000000 4,363 14 Feb 2026 Common Stock 4,362 Direct F3, F6
transaction BSX Restricted Stock Units Options Exercise $0 -3,960 -100% $0.000000 0 16 Feb 2026 Common Stock 3,960 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2 On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F3 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F5 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
F6 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
F7 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.